
CRBP
Corbus
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
consensus rating "Strong Buy"
RSI Overbought
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About CRBP
Corbus Pharmaceuticals Holdings, Inc.
An immunology company that develops novel therapeutics for the treatment of inflammatory diseases
500 River Ridge Drive
, Norwood
, Massachusetts 02062
--
Corbus Pharmaceuticals Holdings, Inc., was incorporated under the laws of the State of Delaware on April 24, 2009. Corbus is a precision oncology company with a diverse product portfolio dedicated to helping people beat serious diseases by bringing innovative scientific methods to widely understood biological pathways. The company's pipeline consists of two experimental drugs for solid tumors: CRB-701, a next-generation antibody-drug conjugate that targets the expression of Nectin-4 on cancer cells to release cytotoxic payloads, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells.
Company Financials
EPS
CRBP has released its 2024 Q4 earnings. EPS was reported at -0.78, versus the expected -1.26, beating expectations. The chart below visualizes how CRBP has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available